Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
Cancer Biol Ther. 2021 Dec 2:1-12. doi: 10.1080/15384047.2021.1976567. Online ahead of print.ABSTRACTThe five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained a dismal 9% for approximately 40 years with an urgent need for novel therapeutic interventions. ONC201 is the founding member of the imipridone class, comprised of orally bioavailable small molecules that have shown efficacy in multiple tumor types both in animal models and in Phase I/II clinical trials. ONC201 is a potent inducer of the tumor necrosis factor related apoptosis inducing ligand (TRAIL) pathway. TRAIL is an innate immune mecha...
Source: Cancer Biology and Therapy - December 3, 2021 Category: Cancer & Oncology Authors: Aakash V Jhaveri Lanlan Zhou Marie D Ralff Young S Lee Arunasalam Navaraj Benedito A Carneiro Howard Safran Varun V Prabhu Eric A Ross Seulki Lee Wafik S El-Deiry Source Type: research

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
Cancer Biol Ther. 2021 Dec 2:1-12. doi: 10.1080/15384047.2021.1976567. Online ahead of print.ABSTRACTThe five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained a dismal 9% for approximately 40 years with an urgent need for novel therapeutic interventions. ONC201 is the founding member of the imipridone class, comprised of orally bioavailable small molecules that have shown efficacy in multiple tumor types both in animal models and in Phase I/II clinical trials. ONC201 is a potent inducer of the tumor necrosis factor related apoptosis inducing ligand (TRAIL) pathway. TRAIL is an innate immune mecha...
Source: Cancer Biology and Therapy - December 3, 2021 Category: Cancer & Oncology Authors: Aakash V Jhaveri Lanlan Zhou Marie D Ralff Young S Lee Arunasalam Navaraj Benedito A Carneiro Howard Safran Varun V Prabhu Eric A Ross Seulki Lee Wafik S El-Deiry Source Type: research

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo
Cancer Biol Ther. 2021 Dec 2:1-12. doi: 10.1080/15384047.2021.1976567. Online ahead of print.ABSTRACTThe five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained a dismal 9% for approximately 40 years with an urgent need for novel therapeutic interventions. ONC201 is the founding member of the imipridone class, comprised of orally bioavailable small molecules that have shown efficacy in multiple tumor types both in animal models and in Phase I/II clinical trials. ONC201 is a potent inducer of the tumor necrosis factor related apoptosis inducing ligand (TRAIL) pathway. TRAIL is an innate immune mecha...
Source: Cancer Biology and Therapy - December 3, 2021 Category: Cancer & Oncology Authors: Aakash V Jhaveri Lanlan Zhou Marie D Ralff Young S Lee Arunasalam Navaraj Benedito A Carneiro Howard Safran Varun V Prabhu Eric A Ross Seulki Lee Wafik S El-Deiry Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis
Cancer Biol Ther. 2021 Nov 1:1-9. doi: 10.1080/15384047.2021.1996139. Online ahead of print.ABSTRACTHemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. Lymphoma-associated hemophagocytic lymphohistiocytosis (LAHS) is a kind of secondary HLH (sHLH). It suffers the worst outcome among sHLH. However, there is no standard treatment strategy. The argument mainly focuses on whether an HLH-directed or malignancy-directed approach should initially be adopted. Etoposide is one of the key drugs in HLH treatment and also shows activity...
Source: Cancer Biology and Therapy - November 2, 2021 Category: Cancer & Oncology Authors: Yue Song Jingshi Wang Yini Wang Lin Wu Zhao Wang Source Type: research

Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells
Cancer Biol Ther. 2021 Oct 31:1-8. doi: 10.1080/15384047.2021.1982599. Online ahead of print.ABSTRACTBiguanide drugs (metformin and phenformin) have drawn interest for potential cancer treatments, and laboratory studies show that some cancer cells are selectively sensitive to growth-inhibitory effects of biguanides. Examining metabolic pathways affected by biguanide treatments in cancer cells that are highly sensitive to biguanides, we found that biguanide treatment depletes cellular levels of both aspartate and NAD+. Experiments to replenish these metabolites or block steps of the aspartate-malate shuttle suggest that dep...
Source: Cancer Biology and Therapy - November 1, 2021 Category: Cancer & Oncology Authors: Ellen Tully Santosh Bharti Juhyung Woo Zaver Bhujwalla Edward Gabrielson Source Type: research

Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells
Cancer Biol Ther. 2021 Oct 31:1-8. doi: 10.1080/15384047.2021.1982599. Online ahead of print.ABSTRACTBiguanide drugs (metformin and phenformin) have drawn interest for potential cancer treatments, and laboratory studies show that some cancer cells are selectively sensitive to growth-inhibitory effects of biguanides. Examining metabolic pathways affected by biguanide treatments in cancer cells that are highly sensitive to biguanides, we found that biguanide treatment depletes cellular levels of both aspartate and NAD+. Experiments to replenish these metabolites or block steps of the aspartate-malate shuttle suggest that dep...
Source: Cancer Biology and Therapy - November 1, 2021 Category: Cancer & Oncology Authors: Ellen Tully Santosh Bharti Juhyung Woo Zaver Bhujwalla Edward Gabrielson Source Type: research

MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3
This study could yield new information about the mechanisms of LUAD.PMID:34711122 | DOI:10.1080/15384047.2021.1973819 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 29, 2021 Category: Cancer & Oncology Authors: Ming Zhang Xiang Lan Yong Chen Source Type: research

MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3
This study could yield new information about the mechanisms of LUAD.PMID:34711122 | DOI:10.1080/15384047.2021.1973819 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 29, 2021 Category: Cancer & Oncology Authors: Ming Zhang Xiang Lan Yong Chen Source Type: research

MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3
This study could yield new information about the mechanisms of LUAD.PMID:34711122 | DOI:10.1080/15384047.2021.1973819 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 29, 2021 Category: Cancer & Oncology Authors: Ming Zhang Xiang Lan Yong Chen Source Type: research

NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction
Cancer Biol Ther. 2021 Oct 27:1-11. doi: 10.1080/15384047.2021.1990631. Online ahead of print.ABSTRACTNop2/Sun RNA methyltransferase (NSUN6) is an RNA 5-methyl cytosine (5mC) transferase with little information known of its function in cancer and response to cancer therapy. Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers. Mechanistically, our results show that NSUN6 controls response to TMZ ...
Source: Cancer Biology and Therapy - October 27, 2021 Category: Cancer & Oncology Authors: Chidiebere U Awah Jan Winter Claudiane M Mazdoom Olorunseun O Ogunwobi Source Type: research

NSUN6, an RNA methyltransferase of 5-mC controls glioblastoma response to temozolomide (TMZ) via NELFB and RPS6KB2 interaction
Cancer Biol Ther. 2021 Oct 27:1-11. doi: 10.1080/15384047.2021.1990631. Online ahead of print.ABSTRACTNop2/Sun RNA methyltransferase (NSUN6) is an RNA 5-methyl cytosine (5mC) transferase with little information known of its function in cancer and response to cancer therapy. Here, we show that NSUN6 methylates both large and small RNA in glioblastoma and controls glioblastoma response to temozolomide with or without influence of the MGMT promoter status, with high NSUN6 expression conferring survival benefit to glioblastoma patients and in other cancers. Mechanistically, our results show that NSUN6 controls response to TMZ ...
Source: Cancer Biology and Therapy - October 27, 2021 Category: Cancer & Oncology Authors: Chidiebere U Awah Jan Winter Claudiane M Mazdoom Olorunseun O Ogunwobi Source Type: research

Multimodality therapy in metastatic pancreas cancer with a < em > BRCA < /em > mutation and durable long-term outcome: biology, intervention, or both?
Cancer Biol Ther. 2021 Oct 25:1-5. doi: 10.1080/15384047.2021.1991739. Online ahead of print.ABSTRACTMetastatic pancreatic adenocarcinoma (PDAC) is a rapidly lethal disease, with less than half of patients surviving 12 months, and 5-year survival approximately 3%. These outcomes are in large part due to a lack of effective medical and surgical therapies for metastatic PDAC. Herein, we present the case of a patient with oligometastatic liver recurrence of BRCA2-mutated PDAC following a curative-intent resection. Through a combination of systemic chemotherapy, metastasectomy, radiotherapy, and subsequent targeted therapy wit...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Thomas L Sutton Aaron Grossberg Frederick Ey Eileen M O'Reilly Brett C Sheppard Source Type: research

Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing
Cancer Biol Ther. 2021 Oct 25:1-20. doi: 10.1080/15384047.2021.1992233. Online ahead of print.ABSTRACTTumor metastasis is the leading cause of cancer mortality, often characterized by abnormal cell growth and invasion to distant organs. The cancer invasion due to epithelial to mesenchymal transition is affected by metabolic and oxygen availability in the tumor-associated micro-environment. A precise alteration in oxygen and metabolic signaling between healthy and metastatic cells is a substantial probe for understanding tumor progression and metastasis. Molecular heterogeneity in the tumor microenvironment help to sustain ...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Vinod S Bisht Kuldeep Giri Deepak Kumar Kiran Ambatipudi Source Type: research

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer < em > in vitro < /em > and < em > in vivo < /em >
Cancer Biol Ther. 2021 Oct 25:1-10. doi: 10.1080/15384047.2021.1977067. Online ahead of print.ABSTRACTONC201 demonstrated promising activity in patients with advanced endometrial cancer in a Phase I clinical trial. ONC201 activates the integrated stress response (ISR) and upregulates TRAIL and its receptor DR5. We hypothesized ONC201 upregulation of DR5 could sensitize tumors to TRAIL and combination of ONC201 and TRAIL would lead to enhanced cell death in endometrial cancer models. Five endometrial cancer cell lines AN3CA, HEC1A, Ishikawa, RL952, and KLE as well as a murine xenograft model were treated with ONC201 alone o...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Jocelyn E Ray Marie D Ralff Aakash Jhaveri Lanlan Zhou David T Dicker Eric A Ross Wafik S El-Deiry Source Type: research

Multimodality therapy in metastatic pancreas cancer with a < em > BRCA < /em > mutation and durable long-term outcome: biology, intervention, or both?
Cancer Biol Ther. 2021 Oct 25:1-5. doi: 10.1080/15384047.2021.1991739. Online ahead of print.ABSTRACTMetastatic pancreatic adenocarcinoma (PDAC) is a rapidly lethal disease, with less than half of patients surviving 12 months, and 5-year survival approximately 3%. These outcomes are in large part due to a lack of effective medical and surgical therapies for metastatic PDAC. Herein, we present the case of a patient with oligometastatic liver recurrence of BRCA2-mutated PDAC following a curative-intent resection. Through a combination of systemic chemotherapy, metastasectomy, radiotherapy, and subsequent targeted therapy wit...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Thomas L Sutton Aaron Grossberg Frederick Ey Eileen M O'Reilly Brett C Sheppard Source Type: research

Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing
Cancer Biol Ther. 2021 Oct 25:1-20. doi: 10.1080/15384047.2021.1992233. Online ahead of print.ABSTRACTTumor metastasis is the leading cause of cancer mortality, often characterized by abnormal cell growth and invasion to distant organs. The cancer invasion due to epithelial to mesenchymal transition is affected by metabolic and oxygen availability in the tumor-associated micro-environment. A precise alteration in oxygen and metabolic signaling between healthy and metastatic cells is a substantial probe for understanding tumor progression and metastasis. Molecular heterogeneity in the tumor microenvironment help to sustain ...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Vinod S Bisht Kuldeep Giri Deepak Kumar Kiran Ambatipudi Source Type: research

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer < em > in vitro < /em > and < em > in vivo < /em >
Cancer Biol Ther. 2021 Oct 25:1-10. doi: 10.1080/15384047.2021.1977067. Online ahead of print.ABSTRACTONC201 demonstrated promising activity in patients with advanced endometrial cancer in a Phase I clinical trial. ONC201 activates the integrated stress response (ISR) and upregulates TRAIL and its receptor DR5. We hypothesized ONC201 upregulation of DR5 could sensitize tumors to TRAIL and combination of ONC201 and TRAIL would lead to enhanced cell death in endometrial cancer models. Five endometrial cancer cell lines AN3CA, HEC1A, Ishikawa, RL952, and KLE as well as a murine xenograft model were treated with ONC201 alone o...
Source: Cancer Biology and Therapy - October 26, 2021 Category: Cancer & Oncology Authors: Jocelyn E Ray Marie D Ralff Aakash Jhaveri Lanlan Zhou David T Dicker Eric A Ross Wafik S El-Deiry Source Type: research

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer
Cancer Biol Ther. 2021 Oct 10:1-7. doi: 10.1080/15384047.2021.1980312. Online ahead of print.ABSTRACTBACKGROUND: The technique to analyze circulating tumor DNA (ctDNA) in body fluid (so-called "liquid biopsy") is recently developed.AIMS: Our aim was to assess the utility of liquid biopsy for predicting progression of pancreatic ductal adenocarcinoma (PDAC) after surgical resection or chemotherapy.METHODS: A total of 72 patients with PDAC were retrospectively enrolled for this study, 33 treated surgically and 39 given chemotherapy, either FOLFIRINOX (oxaliplatin/irinotecan/fluorouracil/leucovorin) or gemcitabine p...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Soichiro Ako Hironari Kato Kazuhiro Nouso Hideaki Kinugasa Hiroyuki Terasawa Hiroshi Matushita Saimon Takada Yosuke Saragai Sho Mizukawa Shinichiro Muro Daisuke Uchida Takeshi Tomoda Kazuyuki Matsumoto Shigeru Horiguchi Daisuke Nobuoka Ryuichi Yoshida Yuz Source Type: research

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
Cancer Biol Ther. 2021 Oct 10:1-10. doi: 10.1080/15384047.2021.1967036. Online ahead of print.ABSTRACTGuanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Previous studies revealed that linaclotide, an oral GUCY2C agonist formulated for gastric release, did not persist to activate guanylyl cyclase signaling in the distal rectum. Dolcanatide is an investigational oral uroguanylin anal...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: David S Weinberg Nathan R Foster Gary Della'Zanna Ryan P McMurray Walter K Kraft Angela Pallotto David M Kastenberg Leo C Katz Christopher H Henry Stephanie M Moleski Paul J Limburg Scott A Waldman Source Type: research

Correction
Cancer Biol Ther. 2021 Oct 10:1. doi: 10.1080/15384047.2021.1982143. Online ahead of print.NO ABSTRACTPMID:34632928 | DOI:10.1080/15384047.2021.1982143 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Source Type: research

Ibrutinib's off-target mechanism: cause for dose optimization
Cancer Biol Ther. 2021 Oct 10:1-3. doi: 10.1080/15384047.2021.1980313. Online ahead of print.ABSTRACTIbrutinib (Imbruvica®, 2013) is a Bruton's tyrosine kinase (BTK) inhibitor approved for multiple B-cell malignancies and cGVHD. Its treatment is associated with increased risk of cardiac adverse events. Atrial fibrillation is a common cause of therapy discontinuation and interruptions, which have been correlated with shorter progression-free survival in chronic lymphocyte leukemia (CLL) patients. Recently, Xiao et al. identified that ibrutinib-mediated atrial fibrillation is likely due to off-target CSK inhibition. Give...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Sara M Zimmerman Cody J Peer William D Figg Source Type: research

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer
Cancer Biol Ther. 2021 Oct 10:1-7. doi: 10.1080/15384047.2021.1980312. Online ahead of print.ABSTRACTBACKGROUND: The technique to analyze circulating tumor DNA (ctDNA) in body fluid (so-called "liquid biopsy") is recently developed.AIMS: Our aim was to assess the utility of liquid biopsy for predicting progression of pancreatic ductal adenocarcinoma (PDAC) after surgical resection or chemotherapy.METHODS: A total of 72 patients with PDAC were retrospectively enrolled for this study, 33 treated surgically and 39 given chemotherapy, either FOLFIRINOX (oxaliplatin/irinotecan/fluorouracil/leucovorin) or gemcitabine p...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Soichiro Ako Hironari Kato Kazuhiro Nouso Hideaki Kinugasa Hiroyuki Terasawa Hiroshi Matushita Saimon Takada Yosuke Saragai Sho Mizukawa Shinichiro Muro Daisuke Uchida Takeshi Tomoda Kazuyuki Matsumoto Shigeru Horiguchi Daisuke Nobuoka Ryuichi Yoshida Yuz Source Type: research

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
Cancer Biol Ther. 2021 Oct 10:1-10. doi: 10.1080/15384047.2021.1967036. Online ahead of print.ABSTRACTGuanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Previous studies revealed that linaclotide, an oral GUCY2C agonist formulated for gastric release, did not persist to activate guanylyl cyclase signaling in the distal rectum. Dolcanatide is an investigational oral uroguanylin anal...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: David S Weinberg Nathan R Foster Gary Della'Zanna Ryan P McMurray Walter K Kraft Angela Pallotto David M Kastenberg Leo C Katz Christopher H Henry Stephanie M Moleski Paul J Limburg Scott A Waldman Source Type: research

Correction
Cancer Biol Ther. 2021 Oct 10:1. doi: 10.1080/15384047.2021.1982143. Online ahead of print.NO ABSTRACTPMID:34632928 | DOI:10.1080/15384047.2021.1982143 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Source Type: research

Ibrutinib's off-target mechanism: cause for dose optimization
Cancer Biol Ther. 2021 Oct 10:1-3. doi: 10.1080/15384047.2021.1980313. Online ahead of print.ABSTRACTIbrutinib (Imbruvica®, 2013) is a Bruton's tyrosine kinase (BTK) inhibitor approved for multiple B-cell malignancies and cGVHD. Its treatment is associated with increased risk of cardiac adverse events. Atrial fibrillation is a common cause of therapy discontinuation and interruptions, which have been correlated with shorter progression-free survival in chronic lymphocyte leukemia (CLL) patients. Recently, Xiao et al. identified that ibrutinib-mediated atrial fibrillation is likely due to off-target CSK inhibition. Give...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Sara M Zimmerman Cody J Peer William D Figg Source Type: research

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer
Cancer Biol Ther. 2021 Oct 10:1-7. doi: 10.1080/15384047.2021.1980312. Online ahead of print.ABSTRACTBACKGROUND: The technique to analyze circulating tumor DNA (ctDNA) in body fluid (so-called "liquid biopsy") is recently developed.AIMS: Our aim was to assess the utility of liquid biopsy for predicting progression of pancreatic ductal adenocarcinoma (PDAC) after surgical resection or chemotherapy.METHODS: A total of 72 patients with PDAC were retrospectively enrolled for this study, 33 treated surgically and 39 given chemotherapy, either FOLFIRINOX (oxaliplatin/irinotecan/fluorouracil/leucovorin) or gemcitabine p...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Soichiro Ako Hironari Kato Kazuhiro Nouso Hideaki Kinugasa Hiroyuki Terasawa Hiroshi Matushita Saimon Takada Yosuke Saragai Sho Mizukawa Shinichiro Muro Daisuke Uchida Takeshi Tomoda Kazuyuki Matsumoto Shigeru Horiguchi Daisuke Nobuoka Ryuichi Yoshida Yuz Source Type: research

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
Cancer Biol Ther. 2021 Oct 10:1-10. doi: 10.1080/15384047.2021.1967036. Online ahead of print.ABSTRACTGuanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression of the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with a GUCY2C agonist may be an effective targeted chemoprevention agent. Previous studies revealed that linaclotide, an oral GUCY2C agonist formulated for gastric release, did not persist to activate guanylyl cyclase signaling in the distal rectum. Dolcanatide is an investigational oral uroguanylin anal...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: David S Weinberg Nathan R Foster Gary Della'Zanna Ryan P McMurray Walter K Kraft Angela Pallotto David M Kastenberg Leo C Katz Christopher H Henry Stephanie M Moleski Paul J Limburg Scott A Waldman Source Type: research

Correction
Cancer Biol Ther. 2021 Oct 10:1. doi: 10.1080/15384047.2021.1982143. Online ahead of print.NO ABSTRACTPMID:34632928 | DOI:10.1080/15384047.2021.1982143 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Source Type: research

Ibrutinib's off-target mechanism: cause for dose optimization
Cancer Biol Ther. 2021 Oct 10:1-3. doi: 10.1080/15384047.2021.1980313. Online ahead of print.ABSTRACTIbrutinib (Imbruvica®, 2013) is a Bruton's tyrosine kinase (BTK) inhibitor approved for multiple B-cell malignancies and cGVHD. Its treatment is associated with increased risk of cardiac adverse events. Atrial fibrillation is a common cause of therapy discontinuation and interruptions, which have been correlated with shorter progression-free survival in chronic lymphocyte leukemia (CLL) patients. Recently, Xiao et al. identified that ibrutinib-mediated atrial fibrillation is likely due to off-target CSK inhibition. Give...
Source: Cancer Biology and Therapy - October 11, 2021 Category: Cancer & Oncology Authors: Sara M Zimmerman Cody J Peer William D Figg Source Type: research